The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•25 March 2026•

1 min read

Alteogen and Biogen Sign Exclusive License Agreement for Subcutaneous Biologics

Key Facts

1Alteogen entered into an exclusive license agreement with Biogen for the development of subcutaneous formulations.

2Biogen will utilize Alteogen's ALT-B4 (Hybrozyme technology) for two biologic products.

Alteogen Inc. has entered into an exclusive license agreement with Biogen Inc. to develop subcutaneous formulations of biologic drugs. Under the terms of the deal, Biogen will utilize Alteogen's proprietary ALT-B4 (Hybrozyme) technology for two specific biologic products. This partnership grants Biogen the exclusive rights to develop and commercialize these new formulations globally, strengthening its product pipeline. The move aims to transition traditional intravenous treatments into more convenient subcutaneous injections, significantly improving patient delivery and convenience. While specific financial terms were not disclosed, the agreement serves as a major validation of Alteogen's technology platform. Investors view this collaboration as a positive step for both companies within the competitive biotechnology sector.